Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 12/20 | 0.66 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | INSR | P06213 | 2/20 | 0.55 |
| ▸ | MET | P08581 | 2/20 | 0.55 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | TEK | Q02763 | 2/20 | 0.55 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31592369 | 0.92 | IGF1R (0.67) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL31592587 | 0.90 | IGF1R (0.52) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL31592402 | 0.87 | IGF1R (0.69) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL31592387 | 0.84 | IGF1R (0.66) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL31592209 | 0.82 | IGF1R (0.54) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL31592501 | 0.82 | IGF1R (0.66) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL31592411 | 0.81 | IGF1R (0.62) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL31592408 | 0.81 | IGF1R (0.70) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL31592256 | 0.80 | IGF1R (0.85) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL31592309 | 0.80 | IGF1R (0.69) | IGF1REGFRINSRMETCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | IGF1R 1/4885EGFR 223/4885INSR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.